---
schema_version: "secwatch.filing_event.v1"
accession: "0001200375-22-000025"
form_type: "8-K"
ticker: "CDXS"
cik: "0001200375"
company_name: "CODEXIS, INC."
filed_at: "2022-07-14T23:59:59+00:00"
generated_at: "2026-06-24T14:48:27.906181+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Codexis cuts FY2022 revenue guidance to $135M-$141M; preliminary Q2 revenue ~$38M

## Summary
- Preliminary Q2 2022 total revenue ~$38M; full-year guidance reduced to $135M-$141M.
- Product revenue guidance unchanged at $112M-$118M; Pfizer product now at low end of $75M-$80M range, offset by other customers.
- Gross margin on product revenue maintained at 65% to 70%.
- CEO cites fewer new deals and lower-than-expected R&D revenue from existing customers as reason for reduction.
- Final Q2 results to be reported on August 4, 2022.

## SEC filing metadata
- accession: 0001200375-22-000025
- form_type: 8-K
- ticker: CDXS
- cik: 0001200375
- company_name: CODEXIS, INC.
- filed_at: 2022-07-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1200375/000120037522000025/0001200375-22-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1200375/000120037522000025/cdxs-20220714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001200375-22-000025
- JSON: https://secwatch.observer/filing/0001200375-22-000025.json
- Plain text: https://secwatch.observer/filing/0001200375-22-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.